1 Worldometer. COVID-19 CORONAVIRUS OUTBREAK, 2020).
2 Organization, W. H. Draft landscape of COVID-19 candidate vaccines. 11 (2020). <https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines>.
3 Burki, T. K. Completion of clinical trials in light of COVID-19. Lancet Respir Med, doi:10.1016/S2213-2600(20)30460-4 (2020).
4 National Institute of Health, U. Clinical trials of monoclonal antibodies to prevent COVID-19 now enrolling, <https://www.nih.gov/news-events/news-releases/clinical-trials-monoclonal-antibodies-prevent-covid-19-now-enrolling> (2020).
5 Wooding, D. J. & Bach, H. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 26, 1436-1446, doi:10.1016/j.cmi.2020.08.005 (2020).
6 Cheng, Y. et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 24, 44-46, doi:10.1007/s10096-004-1271-9 (2005).
7 Rajendran, K. et al. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. Journal of medical virology 92, 1475-1483, doi:10.1002/jmv.25961 (2020).
8 Verkerke, H. P. & Maier, C. L. Towards characterized convalescent plasma for COVID-19: The dose matters. EClinicalMedicine 26, 100545, doi:10.1016/j.eclinm.2020.100545 (2020).
9 Kreer, C. et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182, 1663-1673, doi:10.1016/j.cell.2020.08.046 (2020).
10 Long, Q. X. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nature medicine 26, 1200-1204, doi:10.1038/s41591-020-0965-6 (2020).
11 Choe, P. G. et al. MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015. Emerging infectious diseases 23, 1079-1084, doi:10.3201/eid2307.170310 (2017).
12 Anderson, D. E. et al. Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2. Emerg Microbes Infect 9, 900-902, doi:10.1080/22221751.2020.1761267 (2020).
13 Payne, D. C. et al. Persistence of Antibodies against Middle East Respiratory Syndrome Coronavirus. Emerging infectious diseases 22, 1824-1826, doi:10.3201/eid2210.160706 (2016).
14 Cao, W. C., Liu, W., Zhang, P. H., Zhang, F. & Richardus, J. H. Disappearance of antibodies to SARS-associated coronavirus after recovery. The New England journal of medicine 357, 1162-1163, doi:10.1056/NEJMc070348 (2007).
15 Kiyuka, P. K. et al. Human Coronavirus NL63 Molecular Epidemiology and Evolutionary Patterns in Rural Coastal Kenya. The Journal of infectious diseases 217, 1728-1739, doi:10.1093/infdis/jiy098 (2018).
16 Tan, C. W. et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nature biotechnology 38, 1073-1078, doi:10.1038/s41587-020-0631-z (2020).
17 Jeffrey Seow, C. G., Blair Merrick, Sam Acors, Kathryn J.A. Steel, Oliver Hemmings, Aoife O'Bryne, Neophytos Kouphou, Suzanne Pickering, Rui Galao, Gilberto Betancor, Harry D Wilson, Adrian W Signell, Helena Winstone, Claire Kerridge, Nigel Temperton, Luke Snell, Karen Bisnauthsing, Amelia Moore, Adrian Green, Lauren Martinez, Brielle Stokes, Johanna Honey, Alba Izquierdo-Barras, Gill Arbane, Amita Patel, Lorcan OConnell, Geraldine O Hara, Eithne MacMahon, Sam Douthwaite, Gaia Nebbia, Rahul Batra, Rocio Martinez-Nunez, Jonathan D. Edgeworth, Stuart J.D. Neil, Michael H. Malim, Katie Doores. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. (2020). <https://www.medrxiv.org/content/10.1101/2020.07.09.20148429v1>.
18 Woodruff, M. C. et al. Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nature immunology, doi:10.1038/s41590-020-00814-z (2020).
19 Fierz, W. & Walz, B. Antibody Dependent Enhancement Due to Original Antigenic Sin and the Development of SARS. Frontiers in immunology 11, 1120, doi:10.3389/fimmu.2020.01120 (2020).
20 Chu, C. M. et al. Initial viral load and the outcomes of SARS. CMAJ 171, 1349-1352, doi:10.1503/cmaj.1040398 (2004).
21 Hung, I. F. et al. Viral loads in clinical specimens and SARS manifestations. Emerging infectious diseases 10, 1550-1557, doi:10.3201/eid1009.040058 (2004).
22 Zachariah, P. et al. Symptomatic Infants have Higher Nasopharyngeal SARS-CoV-2 Viral Loads but Less Severe Disease than Older Children. Clin Infect Dis, doi:10.1093/cid/ciaa608 (2020).
23 Estcourt, L. J. & Roberts, D. J. Convalescent plasma for covid-19. BMJ (Clinical research ed 370, m3516, doi:10.1136/bmj.m3516 (2020).
24 Liu, S. T. H. et al. Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. Nature medicine, doi:10.1038/s41591-020-1088-9 (2020).
25 Focosi, D., Anderson, A. O., Tang, J. W. & Tuccori, M. Convalescent Plasma Therapy for COVID-19: State of the Art. Clinical microbiology reviews 33, e00072-00020, doi:10.1128/CMR.00072-20 (2020).
26 Harvala, H. et al. Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020. Euro Surveill 25, 1-7, doi:10.2807/1560-7917.ES.2020.25.28.2001260 (2020).
27 Waggoner, J. J. et al. Homotypic Dengue Virus Reinfections in Nicaraguan Children. The Journal of infectious diseases 214, 986-993, doi:10.1093/infdis/jiw099 (2016).
28 Wijesinghe, A. et al. Phenotype and functionality of follicular helper T cells in patients with acute dengue infection. Journal of biomedical science 27, 50, doi:10.1186/s12929-020-00641-2 (2020).
29 Organization, W. H. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance. (WHO, 2020).
30 Epidemiology unit, M. o. H., Sri Lanka. Coronavirus disease 2019 (COVID-19) - Situation Report – 31.08.2020. (Epidemiology Uni, 2020).
31 Tan CW, C. W., Qin X, Liu P, Chen MI-C, Tiu C, Hu Z, Chen VC-W, Young BE, Sia WR, Tan Y-J, Foo R, Yi Y, Lye DC, Anderson DE, Wang, L.-F A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nature biotechnology, doi:10.21203/rs.3.rs-24574/v1 (2020).